Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphomaLing Huang(Guangdong Academy of Medical Sciences), Wenyu Li(Guangdong Academy of Medical Sciences)Frontiers in ImmunologyNovember 28, 202510.3389/fimmu.2025.1683550Cited by 1SaveCiteExport RISWatch citationsRelated PapersHigher High-Sensitivity C Reactive Protein is Associated with Future Premature Ventricular Contraction: a Community Based Prospective Cohort Study|Scientific Reports|2018|15